|
|
|
|
| LEADER |
01000naa a22002652c 4500 |
| 001 |
NLM393596281 |
| 003 |
DE-627 |
| 005 |
20251004232314.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
251004s2025 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202506373
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1589.xml
|
| 035 |
|
|
|a (DE-627)NLM393596281
|
| 035 |
|
|
|a (NLM)41045103
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Kim, Seunghee
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a LDI, A Lipid Droplet Inhibitor, Disrupts Lipid Accumulation and Modulates Hepatic Lipid Profiles in Fatty Liver
|
| 264 |
|
1 |
|c 2025
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 04.10.2025
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status Publisher
|
| 520 |
|
|
|a © 2025 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Excessive lipid droplet accumulation in hepatocytes drives the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), often leading to inflammation and fibrosis. As obesity and metabolic syndrome rise, MASLD has become a global concern, spurring research into effective treatments. Here, the design of a Lipid droplet inhibitor (LDI) is presented, incorporating porous silica nanostructures along with PKCα C1A and Candida Rugosa lipase, aimed at directly degrading lipid droplets. Through its dual-functional design, this nanostructure captures diacylglycerol using PKCα C1A while hydrolyzing triacylglycerol into smaller molecular fragments via the lipase. Notably, the amphiphilic biomolecules in LDI facilitate the formation of a Pickering emulsion, ensuring stable localization at the lipid-water interface for efficient interaction with lipid droplets. LDI reduces lipid droplet formation and triglyceride levels in palmitic acid-treated HepG2 cells. In a high-fat diet-induced MASLD model, it alleviateds liver pathology and, lowered injury scores by up to 84%. Furthermore, lipidomic analysis confirmed that LDI effectively modulated the hepatic lipid profile, suggesting its potential as a nanoplatform for counteracting lipid droplet accumulation
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a dual‐function nanostructure
|
| 650 |
|
4 |
|a interfacial biocatalysis
|
| 650 |
|
4 |
|a lipid droplet degradation
|
| 650 |
|
4 |
|a metabolic dysfunction–associated liver disease (MASLD)
|
| 650 |
|
4 |
|a pickering emulsion
|
| 700 |
1 |
|
|a Kim, Yeojin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Paudel, Sanjita
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kang, In Young
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Suyeon
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Jeesoo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, Sunmi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Koo, Seung-Hoi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Hyun Sung
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jun, Dae Won
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, Jinyoung
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Hyunbeom
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Joonseok
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g (2025) vom: 04. Okt., Seite e06373
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g year:2025
|g day:04
|g month:10
|g pages:e06373
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202506373
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2025
|b 04
|c 10
|h e06373
|